DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for autosomal recessive osteopetrosis 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutosomal recessive osteopetrosis 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autosomal recessive osteopetrosis 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
carbonic anhydrase 2 (CA2) — CA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hydroxymercurydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3K34 · 0.9 Å · ligand 4-(HYDROXYMERCURY)BENZOIC ACID (HGB). Experimental structure, not a prediction.
What the evidence adds up to
Autosomal recessive osteopetrosis 3, caused by homozygous mutation in the OSTM1 gene, accounts for roughly 5% of all autosomal recessive osteopetrosis cases. This form is the most severe among the autosomal recessive osteopetroses, leading to death within the first few years of life. The OSTM1 protein has a trafficking function essential for osteoclast maturation and also plays a primary, direct role in the central nervous system. No drug treatment is described in these abstracts for any form of osteopetrosis.
The current standard of care for autosomal recessive osteopetrosis is transplantation of pluripotent hematopoietic stem cells, but this is a transplant procedure, not a drug. The 2025 review notes that pathogenetic therapy has low efficiency and that etiotropic therapy methods are limited, though it mentions that alternative treatment methods based on innovative technologies are appearing in medical publications without naming any specific drug or compound.
Whole exome sequencing studies of osteopetrosis cohorts confirm that TCIRG1 is the most frequently mutated gene in autosomal recessive osteopetrosis, while OSTM1 mutations are very rare. In one cohort, sequencing identified mutations in known autosomal recessive osteopetrosis genes and in genes very rarely associated with the disease (FERMT3 and USB1), but no therapeutic intervention was tested. The abstracts provide no data on any drug response, survival improvement, or symptom reduction for autosomal recessive osteopetrosis 3.
What is still missing: any clinical trial testing a drug for OSTM1-related osteopetrosis, any preclinical drug screening in OSTM1 models, and any patient stratification beyond genetic diagnosis. Funding for drug development in this ultra-rare, lethal paediatric disease remains absent from these reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Bone · 2022 · 9 citations · open access
OSTM1 pleiotropic roles from osteopetrosis to neurodegeneration
AbstractAutosomal recessive osteopetroses (ARO) are rare genetic skeletal disorders of high clinical and molecular heterogeneity with an estimated frequency of 1:250,000 worldwide. The manifestations are diverse and although individually rare, the various forms contribute to the prevalence of a significant number of affected individuals with considerable morbidity and mortality. Among the ARO classification, the most severe form is the autosomal recessive-5 (OPTB5) osteopetrosis (OMIM 259720 ) that results from homozygous mutation in the OSTM1 gene (607649). OSTM1 mutations account for approximately 5 % of instances of autosomal recessive osteopetrosis and lead to a highly debilitating form of the disease in infancy and death within the first few years of life (Sobacchi et al., 2013) [1] . • OSTM1 is the more severe form of ARO in mice and humans. • The OSTM1 protein trafficking function is essential for osteoclast maturation. • OSTM1 plays a primary and direct role in the central nervous system.
Modern approaches to autosomal-recessive osteopetrosis treatment
AbstractThe review is devoted to modern developments in the treatment of osteopetrosis, the autosomal-recessive form of which has a high endemicity for the indigenous population of Chuvash and Mari El Republicы. Autosomal-recessive osteopetrosis (ARO) is a major medical and social problem, primarily due to the severity of clinical manifestations, low efficiency of pathogenetic therapy and the limitations of etiotropic therapy methods. Until now, the generally accepted standard for treating the autosomal-recessive form is transplantation of pluripotent hematopoietic stem cells. However, information about the development of alternative ARO treatment methods based on innovative technologies appears in medical publications. Therefore, the study of alternative methods of treating this disease is relevant.
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · 2018 · 0 citations · open access
NEW INSIGHTS IN BONE BIOLOGY FROM EXOME SEQUENCING OF RARE SKELETAL DISEASES
AbstractWhole exome sequencing (WES) is a powerful tool to identify new molecules involved in skeletal homeostasis. In particular we used WES to establish the molecular diagnosis of two particular skeletal diseases: osteopetrosis and the acrofrontofacionasal dysostosis 1 (AFFND1). The osteopetroses are a group of rare bone diseases characterized by increased bone density due to the failure in bone resorption. Due to their genetic heterogeneity, WES represents a valuable strategy to identify the genetic defect. We analyzed osteopetrotic patients with autosomal dominant osteopetrosis (ADO) and autosomal recessive osteopetrosis (ARO), which is the most severe form. In our cohort we performed molecular diagnosis of 4 ADOI or ADOII patients that carried mutations in the LRP5 and CLCN7 genes, respectively. The analysis of ARO patients confirmed TCIRG1 as the most frequently mutated gene, identified mutations in the other known ARO genes and in genes very rarely associated with osteopetrosis, namely FERMT3 and USB1. Of note, we demonstrated the causative role of four deep intronic mutations in TCIRG1 gene and two different synonymous changes in the TCIRG1 and CLCN7 genes in the pathogenesis of the disease. In addition, WES helped in the differential diagnosis in a patient who was found to bear a mutation in the FAM20C gene, known to cause Raine syndrome. Regarding AFFND1, this is an extremely rare syndrome, comprising facial and skeletal abnormalities, short stature and intellectual disability. WES found a novel truncating mutation in the neuroblastoma-amplified sequence (NBAS) gene in two Indian patients (c.6237-3C>G). This mutation impaired NBAS functions in HEK293T cells overexpressing the truncated NBAS protein. Furthermore, we demonstrated that NBAS expression in mouse embryos was compatible with a role in bone and brain development and that the depletion of endogenous z-nbas in fish embryos resulted in defective morphogenesis of chondrogenic cranial skeletal elements. Overall, we provided evidence supporting the hypothesis of a causative role of the mutated NBAS gene in the pathogenesis of AFFND1. In conclusion, we effectively exploited WES in the genetic diagnosis of rare skeletal diseases. We also highlighted potential limitations of this approach, specifically with respect to deep intronic mutations and synonymous changes, and underlined the importance to complement WES with analysis at the transcript level and functional validation, when possible.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
